Gastric Leiomyosarcoma

Gastric leiomyosarcoma is a rare, malignant mesenchymal neoplasm arising from the smooth muscle layers of the stomach, most commonly the muscularis propria. It is a subtype of gastrointestinal stromal tumors (GISTs) but is distinguished by its origin from true smooth muscle cells and its immunophenotypic profile (positive for smooth muscle actin and desmin, negative for CD117/c-KIT). Gastric leiomyosarcoma accounts for less than 1% of all gastric tumors in dogs and cats. It is characterized by slow, infiltrative growth, a tendency for local recurrence, and a moderate metastatic potential, primarily to the liver and regional lymph nodes. Clinical signs are often nonspecific and may include chronic vomiting, weight loss, inappetence, and signs of gastrointestinal bleeding such as melena or anemia. Definitive diagnosis requires histopathological evaluation of biopsy samples, and treatment typically involves surgical resection with wide margins. The prognosis is guarded to fair, depending on tumor grade, stage, and completeness of excision.

The exact etiology of gastric leiomyosarcoma is unknown, but several factors are implicated. Chronic inflammation, such as that associated with chronic gastritis, may lead to smooth muscle hyperplasia and subsequent neoplastic transformation. Genetic mutations, particularly in the TP53 tumor suppressor gene and KIT/PDGFRA oncogenes, have been identified in some cases, although gastric leiomyosarcomas are typically negative for KIT mutations. Environmental factors, such as exposure to carcinogens (e.g., nitrosamines, polycyclic aromatic hydrocarbons), may play a role, though evidence is limited. In dogs, no specific viral or bacterial etiologies have been confirmed. Spontaneous mutations in smooth muscle progenitor cells are considered the primary trigger, leading to uncontrolled proliferation and malignant transformation.

Gastric leiomyosarcoma is a rare tumor in both dogs and cats, representing less than 1% of all gastric neoplasms. It occurs most commonly in older animals, with a median age of 10-12 years in dogs and 12-14 years in cats. There is no strong breed predisposition, but large-breed dogs such as Golden Retrievers, Labrador Retrievers, and German Shepherds may be overrepresented. No significant sex predilection has been consistently reported. The tumor is more frequently diagnosed in dogs than in cats. Geographic variation is not well-documented, but the condition is recognized worldwide. The incidence is higher in animals with a history of chronic gastrointestinal disease, though this association is not firmly established.

Gastric leiomyosarcoma arises from the smooth muscle cells of the gastric wall, typically in the muscularis propria. The tumor grows as a firm, nodular mass that may be intraluminal, intramural, or exophytic. As it enlarges, it can cause mechanical obstruction, leading to gastric outflow obstruction if located near the pylorus. The tumor is highly vascular, and central necrosis and ulceration of the overlying mucosa are common, resulting in chronic blood loss and anemia. Histologically, the tumor is composed of interlacing bundles of spindle cells with variable atypia and mitotic activity. High-grade tumors exhibit marked cellular pleomorphism, high mitotic count, and areas of necrosis. Metastasis occurs via hematogenous spread, most commonly to the liver, and less frequently to the lungs and regional lymph nodes. Local invasion into adjacent structures, such as the pancreas or spleen, can occur. The tumor's slow growth and late metastasis contribute to the often chronic clinical course.

Predisposing factors for gastric leiomyosarcoma include advanced age, as the tumor is most common in older animals. Chronic gastric inflammation, such as that caused by Helicobacter pylori infection or chronic gastritis, may increase the risk. Genetic predisposition is suspected in certain breeds, though specific genes have not been identified. Immunosuppression, either due to disease or medication, may also increase susceptibility. Dietary factors, such as high intake of processed foods or exposure to carcinogens, have been hypothesized but not proven. Additionally, animals with a history of other smooth muscle tumors, such as intestinal leiomyosarcoma, may be at higher risk.

Clinical signs of gastric leiomyosarcoma are often insidious and may be present for weeks to months before diagnosis. The most common signs include chronic vomiting, which may be intermittent and unrelated to eating, and weight loss. Inappetence or anorexia is frequently observed. Signs of gastrointestinal bleeding, such as melena (dark, tarry stools) and pallor, are common due to mucosal ulceration. Hematemesis (vomiting blood) may occur in some cases. As the tumor grows, signs of gastric outflow obstruction may develop, including frequent vomiting of undigested food and abdominal distension. In advanced stages, lethargy, weakness, and signs of metastatic disease (e.g., hepatomegaly, jaundice) may be present. Physical examination may reveal a palpable abdominal mass in some cases, though this is not always possible due to the tumor's location. Chronic blood loss can lead to regenerative anemia, which may be detected on laboratory evaluation.

Differential diagnoses for gastric leiomyosarcoma include other gastric neoplasms such as gastric adenocarcinoma, lymphoma, gastrointestinal stromal tumor (GIST), and leiomyoma (benign smooth muscle tumor). Gastric adenocarcinoma is the most common gastric malignancy in dogs and often presents with similar signs, but it tends to be more infiltrative and has a poorer prognosis. Lymphoma may present with diffuse gastric thickening and is often associated with systemic signs. GISTs are histologically similar but are positive for CD117 (c-KIT) and may respond to tyrosine kinase inhibitors. Leiomyoma is benign and typically well-circumscribed with low mitotic activity. Other differentials include chronic gastritis, gastric ulceration, foreign body, and gastric polyps. Diagnostic imaging and histopathology are essential to differentiate these conditions.

The diagnostic approach to gastric leiomyosarcoma begins with a thorough history and physical examination. Initial laboratory tests, including complete blood count (CBC), serum biochemistry, and urinalysis, may reveal anemia, elevated liver enzymes (if metastasis), and hypoalbuminemia. Abdominal radiographs may show a soft tissue mass or gastric wall thickening, but are often nonspecific. Abdominal ultrasonography is the next step and can identify a gastric mass, assess its location, and evaluate for metastasis to the liver or lymph nodes. Fine-needle aspiration (FNA) of the mass can be performed under ultrasound guidance, but cytology may be inconclusive due to the dense nature of the tumor. Endoscopy is highly valuable for direct visualization of the mass, and biopsy samples can be obtained. However, endoscopic biopsies may not reach the deeper layers of the stomach, so surgical biopsy (full-thickness) is often required for definitive diagnosis. Histopathology with immunohistochemistry (IHC) is the gold standard, with positive staining for smooth muscle actin (SMA) and desmin, and negative staining for CD117, CD34, and S100. Computed tomography (CT) may be used for surgical planning and staging, particularly to assess local invasion and metastasis.

Laboratory findings in gastric leiomyosarcoma are often nonspecific but may include: Hematology: Regenerative anemia (due to chronic blood loss) characterized by decreased hematocrit, increased reticulocyte count, and polychromasia. Leukocytosis may be present due to inflammation or stress. Serum Biochemistry: Hypoalbuminemia (due to chronic inflammation or blood loss), elevated liver enzymes (ALT, ALP) if hepatic metastasis is present, and possibly elevated blood urea nitrogen (BUN) and creatinine if dehydration occurs. Electrolyte imbalances, such as hypokalemia, may result from chronic vomiting. Urinalysis: Usually unremarkable, but may show evidence of dehydration (high urine specific gravity) or proteinuria if glomerular disease is concurrent. Blood Gas Analysis: May reveal metabolic alkalosis due to vomiting. Specific Biomarkers: No specific biomarkers are available for gastric leiomyosarcoma, but serum levels of vascular endothelial growth factor (VEGF) may be elevated in some malignancies. Serology/PCR: Not typically indicated unless infectious causes are suspected.

Radiography: Abdominal radiographs may reveal a soft tissue mass in the cranial abdomen, gastric wall thickening, or signs of gastric outflow obstruction (e.g., gastric dilation). However, these findings are nonspecific. Ultrasonography: Abdominal ultrasound is the most useful imaging modality. It typically shows a hypoechoic, heterogeneous mass arising from the gastric wall, often with central necrosis or cavitation. The mass may be intramural or exophytic. Doppler ultrasound can assess vascularity. Ultrasonography is also essential for evaluating the liver and regional lymph nodes for metastasis. Computed Tomography (CT): CT provides detailed cross-sectional images and is superior for assessing the extent of the tumor, local invasion, and metastasis. It is particularly useful for surgical planning. Magnetic Resonance Imaging (MRI): MRI is rarely used for gastric tumors but may be helpful in assessing soft tissue involvement. Endoscopy: Endoscopy allows direct visualization of the gastric lumen and can identify an intraluminal mass, ulceration, or stricture. Biopsy samples can be obtained, but the deep layers may not be sampled adequately. Fluoroscopy: Barium contrast studies may show filling defects or altered gastric motility, but are less commonly used now.

Cytology: Fine-needle aspiration (FNA) of gastric masses may yield spindle cells, but the sample is often nondiagnostic due to the dense, fibrous nature of the tumor. If obtained, cytology may show clusters of spindle cells with moderate anisocytosis and anisokaryosis. Histopathology: Definitive diagnosis requires histopathological examination of a full-thickness biopsy. Grossly, the tumor is a firm, white to tan mass with a whorled appearance. Microscopically, it is composed of interlacing bundles of spindle cells with eosinophilic cytoplasm and elongated, blunt-ended nuclei. Mitotic count is variable; high-grade tumors have >10 mitoses per 10 high-power fields (HPF). Areas of necrosis and hemorrhage are common. Immunohistochemistry (IHC) is essential: positive for smooth muscle actin (SMA) and desmin, negative for CD117 (c-KIT), CD34, and S100. This distinguishes it from GIST (which is CD117 positive) and other sarcomas.

The primary treatment for gastric leiomyosarcoma is surgical resection. Wide surgical excision with clean margins is the goal, which may involve partial gastrectomy (e.g., Billroth I or II procedures) depending on the tumor location. Complete surgical removal offers the best chance for long-term survival. In cases where surgery is not feasible due to metastasis or poor patient condition, palliative options include chemotherapy and radiation therapy. Chemotherapy protocols for sarcomas include doxorubicin (30 mg/m² IV every 3 weeks) or a combination of doxorubicin and cyclophosphamide. However, the response rate is variable, and the efficacy is not well-documented. Radiation therapy may be used for local control, especially if surgical margins are incomplete. Supportive care includes fluid therapy for dehydration, antiemetics (e.g., maropitant 1 mg/kg IV or PO q24h), and gastroprotectants (e.g., omeprazole 1 mg/kg PO q12h). Nutritional support with a highly digestible diet may be necessary. In cases of severe anemia, blood transfusion may be required.

The prognosis for gastric leiomyosarcoma is guarded to fair. Complete surgical excision with clean margins is associated with a median survival time of 12-24 months in dogs. Incomplete margins or high-grade tumors (mitotic count >10 per 10 HPF) are associated with a poorer prognosis, with median survival times of 6-12 months. Metastasis to the liver or other organs at the time of diagnosis significantly worsens the prognosis. The presence of clinical signs such as weight loss and anemia may also indicate a poorer outcome. In cats, the prognosis is similar, though the tumor is even rarer. Regular monitoring for recurrence and metastasis is essential.

Post-treatment follow-up is crucial for early detection of recurrence or metastasis. Recommendations include: Physical examination and abdominal ultrasound every 3 months for the first year, then every 6 months thereafter. Complete blood count and serum biochemistry should be performed at each recheck to monitor for anemia, liver enzyme changes, and overall health. If the patient received chemotherapy, complete blood count should be checked before each dose to assess for myelosuppression. Thoracic radiographs should be taken every 6-12 months to rule out pulmonary metastasis. If clinical signs recur, repeat imaging and possibly biopsy are indicated. Long-term management includes maintaining a high-quality diet and monitoring for signs of gastrointestinal bleeding.

Pearls: 1. Gastric leiomyosarcoma is a rare tumor, but should be considered in older dogs and cats with chronic vomiting and anemia. 2. Endoscopic biopsies may miss the tumor because it arises in the muscularis propria; a full-thickness surgical biopsy is often needed. 3. Immunohistochemistry is essential to differentiate leiomyosarcoma from GIST, as treatment and prognosis differ. 4. Complete surgical excision is the most important prognostic factor. Pitfalls: 1. Do not rely solely on cytology, as it is often nondiagnostic. 2. Avoid assuming a gastric mass is a carcinoma; sarcomas have different biological behavior. 3. Do not delay surgery if the tumor is resectable, as metastasis can occur. 4. Be aware that chemotherapy has limited efficacy in sarcomas, so surgery is the mainstay.

Based on Plumb's Veterinary Drug Handbook, the following protocols may be considered: 1. Doxorubicin: 30 mg/m² IV every 3 weeks, for a total of 4-6 cycles. Monitor for cardiotoxicity and myelosuppression. 2. Cyclophosphamide: 50 mg/m² PO every other day, or 200 mg/m² IV every 3 weeks, often used in combination with doxorubicin. 3. Maropitant (Cerenia): 1 mg/kg IV or PO q24h for vomiting. 4. Omeprazole: 1 mg/kg PO q12h for gastric ulceration. 5. Sucralfate: 0.5-1 g PO q8h, given 30 minutes before meals, for gastric protection. 6. For pain management, consider opioids such as buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or tramadol (2-5 mg/kg PO q8-12h). Adjust dosages for renal or hepatic impairment. Avoid NSAIDs due to risk of gastrointestinal bleeding.

Literature on gastric leiomyosarcoma is limited to case reports and small case series. A retrospective study by Selting et al. (2005) reported on 12 dogs with gastric leiomyosarcoma, finding a median survival time of 12 months with surgical resection. Another study by Cohen et al. (2003) noted that complete excision was associated with longer survival. Immunohistochemical characterization is well-documented, with SMA and desmin positivity and CD117 negativity. Chemotherapy has not been shown to significantly improve outcomes in sarcomas, but doxorubicin-based protocols are often used. Consensus guidelines from ACVIM and ECVIM recommend surgical resection as the primary treatment, with adjunctive therapy considered for high-grade tumors. Further research is needed to establish optimal chemotherapy protocols and prognostic factors.